EICHORCondition: Psoriasis · Obesity · Sponsor: Eli Lilly and Company
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology | Birmingham, Alabama, United States | — |
| Medical Dermatology Specialists | Phoenix, Arizona, United States | — |
| Scottsdale Clinical Trials | Scottsdale, Arizona, United States | — |
| Yuma Clinical Trials | Yuma, Arizona, United States | — |
| Johnson Dermatology | Fort Smith, Arkansas, United States | — |
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| First OC Dermatology Research Inc | Fountain Valley, California, United States | — |
| Avance Clinical Trials | Laguna Niguel, California, United States | — |
| Metropolis Dermatology | Los Angeles, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| Northridge Clinical Trials | Northridge, California, United States | — |
| Cura Clinical Research - Oxnard | Oxnard, California, United States | — |
+ 60 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06588283